Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

87.11
-0.3600-0.41%
Post-market: 87.02-0.0900-0.10%19:30 EDT
Volume:1.09M
Turnover:94.72M
Market Cap:12.27B
PE:-38.14
High:88.46
Open:87.90
Low:85.94
Close:87.47
52wk High:95.49
52wk Low:20.45
Shares:140.86M
Float Shares:122.00M
Volume Ratio:1.09
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:26.36
PE(LYR):-7,144.26

Loading ...

Arrowhead Pharma Director Michael S. Perry Disposes of 11,600 Shares for $1.01 Million

Reuters
·
Aug 21

Arrowhead announces availability of REDEMPLO for FCS in Germany

TIPRANKS
·
Aug 17

People Living with Familial Chylomicronaemia Syndrome (Fcs) in Germany Have Access to Redemplo® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

THOMSON REUTERS
·
Aug 17

Arrowhead Pharmaceuticals Earnings Call Signals Confident Expansion

TIPRANKS
·
Aug 16

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses

Simply Wall St.
·
Aug 11

Arrowhead price target raised to $120 from $115 at H.C. Wainwright

TIPRANKS
·
Aug 07

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)

TIPRANKS
·
Aug 05

U.S. Research Roundup-Ametek, Ball Corp, McDonald's

Reuters
·
Aug 05

Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital

TIPRANKS
·
Aug 05

Arrowhead Publishes Transcript of Fiscal 2026 Third-Quarter Conference Call

Reuters
·
Aug 05

Arrowhead Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Arrowhead Pharma Acquires FDA Rare Pediatric Disease Priority Review Voucher

Reuters
·
Aug 05

Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Fiscal Q3 Loss $1.36, vs. FactSet Est of $1.28 Loss

MT Newswires Live
·
Aug 05

Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth

Reuters
·
Aug 05

Arrowhead Net Loss Widens to $194.28 Million in FY26 Q3; Revenue Rises to $75.25 Million

Reuters
·
Aug 05

Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate

Benzinga Earnings
·
Aug 05

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals Q3 EPS USD -1.36

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals Q3 Operating Income USD -170.093 Million

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals - to Use Voucher for Plozasiran Snda in Severe Hypertriglyceridemia Before End of 2026

THOMSON REUTERS
·
Aug 05